The estimated Net Worth of Douglas P Astry is at least 270 千$ dollars as of 28 November 2008. Douglas Astry owns over 600 units of Surmodics stock worth over 256,603$ and over the last 21 years Douglas sold SRDX stock worth over 13,404$.
Douglas has made over 1 trades of the Surmodics stock since 2008, according to the Form 4 filled with the SEC. Most recently Douglas sold 600 units of SRDX stock worth 13,404$ on 28 November 2008.
The largest trade Douglas's ever made was selling 600 units of Surmodics stock on 28 November 2008 worth over 13,404$. On average, Douglas trades about 46 units every 0 days since 2004. As of 28 November 2008 Douglas still owns at least 6,541 units of Surmodics stock.
You can see the complete history of Douglas Astry stock trades at the bottom of the page.
Douglas's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Over the last 21 years, insiders at Surmodics have traded over 26,204,565$ worth of Surmodics stock and bought 19,725 units worth 436,251$ . The most active insiders traders include Jeffrey C Smith、Gary R Maharaj、Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of 415,014$. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth 706,662$.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: